• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种用于预测分化型甲状腺癌患者预后的模型以及与其他分类系统相比的模型性能。

A model for predicting outcomes in patients with differentiated thyroid cancer and model performance in comparison with other classification systems.

作者信息

Yildirim Emin

机构信息

Department of Surgery, Ankara Oncology Training and Research Hospital, Ankara, Turkey.

出版信息

J Am Coll Surg. 2005 Mar;200(3):378-92. doi: 10.1016/j.jamcollsurg.2004.10.031.

DOI:10.1016/j.jamcollsurg.2004.10.031
PMID:15737848
Abstract

BACKGROUND

This study was performed to determine the prognostic factors for differentiated thyroid cancer, and to establish a mathematical prognostic model.

STUDY DESIGN

A retrospective study was conducted in 347 differentiated thyroid cancer patients. Univariate and multivariate prognostic factor analyses were carried out using the Kaplan-Meier and Cox regression methods.

RESULTS

Without adjustment for treatment in the multivariate analysis, age, tumor size, angioinvasion, and distant metastasis were significant predictors of outcomes. The very low-risk, low-risk, high-risk, and very high-risk groups were identified from the logistic regression equation. Overall and event-free survival estimations at 10 years were 100% and 100% for very low-risk patients, 88% and 75% for low-risk patients, 30% and 16% for high-risk patients, and 5% and 0% for very high-risk patients. Inclusion of treatment in the multivariate analysis showed, in addition to other variables, that both total or near total thyroidectomy (versus thyroidectomy less than total and near total thyroidectomy, p = 0.0002; hazard ratio, 0.4; 95% CI, 0.3-0.7) and adjuvant radioactive iodine treatment (versus no treatment with radioactive iodine, p = 0.0001; hazard ratio, 0.5; 95% CI, 0.2-0.8) were associated with a reduced hazard of death in the followup period. By subgroup analysis, total and near total thyroidectomy, along with radioactive iodine, appeared to provide a survival benefit for all patients except those in the very low-risk group.

CONCLUSIONS

The proposed mathematical model is satisfactory for predicting outcomes. Total and near total thyroidectomy along with radioactive iodine treatment might provide a survival advantage for differentiated thyroid cancer, except for those with very low risk.

摘要

背景

本研究旨在确定分化型甲状腺癌的预后因素,并建立一个数学预后模型。

研究设计

对347例分化型甲状腺癌患者进行了一项回顾性研究。使用Kaplan-Meier法和Cox回归方法进行单因素和多因素预后因素分析。

结果

在多因素分析中,未对治疗进行调整时,年龄、肿瘤大小、血管侵犯和远处转移是预后的重要预测因素。根据逻辑回归方程确定了极低风险、低风险、高风险和极高风险组。极低风险患者10年的总生存率和无事件生存率估计分别为100%和100%,低风险患者为88%和75%,高风险患者为30%和16%,极高风险患者为5%和0%。在多因素分析中纳入治疗因素后发现,除其他变量外,全甲状腺切除或近全甲状腺切除(与小于全甲状腺切除和近全甲状腺切除相比,p = 0.0002;风险比,0.4;95%可信区间,0.3 - 0.7)和辅助放射性碘治疗(与未进行放射性碘治疗相比,p = 0.0001;风险比,0.5;95%可信区间,0.2 - 0.8)与随访期间死亡风险降低相关。通过亚组分析,全甲状腺切除和近全甲状腺切除以及放射性碘似乎为除极低风险组患者外的所有患者提供了生存益处。

结论

所提出的数学模型在预测预后方面令人满意。全甲状腺切除和近全甲状腺切除以及放射性碘治疗可能为分化型甲状腺癌患者提供生存优势,但极低风险患者除外。

相似文献

1
A model for predicting outcomes in patients with differentiated thyroid cancer and model performance in comparison with other classification systems.一种用于预测分化型甲状腺癌患者预后的模型以及与其他分类系统相比的模型性能。
J Am Coll Surg. 2005 Mar;200(3):378-92. doi: 10.1016/j.jamcollsurg.2004.10.031.
2
The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.手术、放射性碘及外照射放疗对分化型甲状腺癌患者临床结局的影响。
Cancer. 1998 Jan 15;82(2):375-88.
3
Implications of prognostic factors and risk groups in the management of differentiated thyroid cancer.预后因素及风险分组在分化型甲状腺癌管理中的意义
Laryngoscope. 2004 Mar;114(3):393-402. doi: 10.1097/00005537-200403000-00001.
4
Management and outcome of recurrent well-differentiated thyroid carcinoma.复发性高分化甲状腺癌的管理与预后
Arch Otolaryngol Head Neck Surg. 2004 Jul;130(7):819-24. doi: 10.1001/archotol.130.7.819.
5
Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4).分化型甲状腺癌。辅助性外照射放疗对甲状腺周围肿瘤浸润患者(pT4期)的影响。
Cancer. 1996 Jan 1;77(1):172-80. doi: 10.1002/(SICI)1097-0142(19960101)77:1<172::AID-CNCR28>3.0.CO;2-1.
6
Prognostic factors in well-differentiated thyroid carcinoma in patients treated and followed in the same institution.在同一机构接受治疗和随访的高分化甲状腺癌患者的预后因素。
Ann Ital Chir. 2006 Mar-Apr;77(2):107-13.
7
Treatment of locally aggressive well-differentiated thyroid cancer.局部侵袭性高分化甲状腺癌的治疗
Int Surg. 2001 Oct-Dec;86(4):213-9.
8
Operative strategy for follicular thyroid cancer in risk groups stratified by pTNM staging.根据pTNM分期对危险组滤泡性甲状腺癌的手术策略
Surg Oncol. 2007 Aug;16(2):107-13. doi: 10.1016/j.suronc.2007.05.004. Epub 2007 Jun 27.
9
Surgical treatment of papillary and follicular thyroid carcinoma.乳头状和滤泡状甲状腺癌的外科治疗
Int Surg. 1996 Jan-Mar;81(1):61-6.
10
Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.乳头状和滤泡状甲状腺癌的病理肿瘤-淋巴结-转移(pTNM)分期:700例患者的回顾性分析
J Clin Endocrinol Metab. 1997 Nov;82(11):3553-62. doi: 10.1210/jcem.82.11.4373.

引用本文的文献

1
Rethinking the prognosis model of differentiated thyroid carcinoma.重新思考分化型甲状腺癌的预后模型。
Front Endocrinol (Lausanne). 2024 Sep 30;15:1419125. doi: 10.3389/fendo.2024.1419125. eCollection 2024.
2
Differentiated Thyroid Carcinoma Long-Term Prognostic Factors.分化型甲状腺癌的长期预后因素。
Int J Surg Oncol. 2024 Sep 10;2024:1067447. doi: 10.1155/2024/1067447. eCollection 2024.
3
Development and Validation of a Risk Scoring System Derived from Meta-Analyses of Papillary Thyroid Cancer.基于甲状腺乳头状癌荟萃分析构建的风险评分系统的开发与验证
Endocrinol Metab (Seoul). 2020 Jun;35(2):435-442. doi: 10.3803/EnM.2020.35.2.435. Epub 2020 Jun 24.
4
Impact of the change from the seventh to eighth edition of the AJCC TNM classification of malignant tumours and comparison with the MACIS prognostic scoring system in non-medullary thyroid cancer.AJCC 肿瘤分期第 7 版到第 8 版变迁对非髓样甲状腺癌的影响及与 MACIS 预后评分系统的比较。
BJS Open. 2019 Jun 28;3(5):623-628. doi: 10.1002/bjs5.50182. eCollection 2019 Oct.
5
Mathematical models applied to thyroid cancer.应用于甲状腺癌的数学模型。
Biophys Rev. 2019 Apr;11(2):183-189. doi: 10.1007/s12551-019-00504-7. Epub 2019 Feb 15.
6
Relationship between lymphovascular invasion and clinicopathological features of papillary thyroid carcinoma.甲状腺乳头状癌的淋巴管侵犯与临床病理特征之间的关系
Bosn J Basic Med Sci. 2017 May 20;17(2):144-151. doi: 10.17305/bjbms.2017.1924.
7
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.2015年美国甲状腺协会成人甲状腺结节和分化型甲状腺癌管理指南:美国甲状腺协会甲状腺结节和分化型甲状腺癌指南工作组
Thyroid. 2016 Jan;26(1):1-133. doi: 10.1089/thy.2015.0020.
8
Histopathological Evidence of Lymph Node Metastasis in Papillary Thyroid Carcinoma.甲状腺乳头状癌淋巴结转移的组织病理学证据
Endocr Pathol. 2015 Sep;26(3):218-28. doi: 10.1007/s12022-015-9382-7.
9
Diagnosis and treatment of patients with thyroid cancer.甲状腺癌患者的诊断与治疗。
Am Health Drug Benefits. 2015 Feb;8(1):30-40.
10
Validation of the QTNM staging system for cancer-specific survival in patients with differentiated thyroid cancer.验证 QTNM 分期系统在分化型甲状腺癌患者中的癌症特异性生存预测价值。
Endocrine. 2014 Jun;46(2):300-8. doi: 10.1007/s12020-013-0078-9. Epub 2013 Oct 31.